Compare Agilent Technologies Inc (A) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Agilent Technologies Inc trades at $149.5 (market cap $42.22B), while State Street SPDR S&P Biotech ETF trades at $158.26. The key difference: Agilent Technologies Inc pays a 0.68% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| A | XBI | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $157.20 | $164.28 |
52-Week Low | $110.24 | $86.92 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
